These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19536002)

  • 1. Assigning resources to health care use for health services research: options and consequences.
    Fishman PA; Hornbrook MC
    Med Care; 2009 Jul; 47(7 Suppl 1):S70-5. PubMed ID: 19536002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges in building disease-based national health accounts.
    Rosen AB; Cutler DM
    Med Care; 2009 Jul; 47(7 Suppl 1):S7-13. PubMed ID: 19536017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic foundations of cost-effectiveness analysis.
    Garber AM; Phelps CE
    J Health Econ; 1997 Feb; 16(1):1-31. PubMed ID: 10167341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics.
    Bridges JF
    Appl Health Econ Health Policy; 2003; 2(4):213-24. PubMed ID: 15119540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis and policy choices: investing in health systems.
    Murray CJ; Kreuser J; Whang W
    Bull World Health Organ; 1994; 72(4):663-74. PubMed ID: 7923545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramsey waits: allocating public health service resources when there is rationing by waiting.
    Gravelle H; Siciliani L
    J Health Econ; 2008 Sep; 27(5):1143-54. PubMed ID: 18468707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis.
    Brandeau ML; Zaric GS; Richter A
    J Health Econ; 2003 Jul; 22(4):575-98. PubMed ID: 12842316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes.
    Hoerger TJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S21-7. PubMed ID: 19536014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategic costs and preferences revelation in the allocation of resources for health care.
    Levaggi L; Levaggi R
    Int J Health Care Finance Econ; 2010 Sep; 10(3):239-56. PubMed ID: 20309636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should "standard gamble" and "'time trade off" utility measurement be used more in mental health research?
    Flood C
    J Ment Health Policy Econ; 2010 Jun; 13(2):65-72. PubMed ID: 20919593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.
    Hill SR; Olson LG; Falck-Ytter Y; Cruz AA; Atkins D; Baumann M; Jaeschke R; Woitalla T; Schünemann HJ;
    Proc Am Thorac Soc; 2012 Dec; 9(5):251-5. PubMed ID: 23256167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of methods for estimating the cost of human immunodeficiency virus-testing interventions.
    Shrestha RK; Sansom SL; Farnham PG
    J Public Health Manag Pract; 2012; 18(3):259-67. PubMed ID: 22473119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation.
    Drummond MF; Aguiar-Ibanez R; Nixon J
    Singapore Med J; 2006 Jun; 47(6):456-61; quiz 462. PubMed ID: 16752012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hospital costs estimation by micro and gross-costing approaches].
    Guerre P; Hayes N; Bertaux AC;
    Rev Epidemiol Sante Publique; 2018 Mar; 66 Suppl 2():S65-S72. PubMed ID: 29525184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of VA health care costs.
    Barnett PG
    Med Care Res Rev; 2003 Sep; 60(3 Suppl):124S-141S. PubMed ID: 15095549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic analysis in dermatology.
    Ellis CN; Reiter KL; Wheeler JR; Fendrick AM
    J Am Acad Dermatol; 2002 Feb; 46(2):271-83. PubMed ID: 11807441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjusting to changes in health: implications for cost-effectiveness analysis.
    Sharma R; Stano M; Haas M
    J Health Econ; 2004 Mar; 23(2):335-51. PubMed ID: 15019760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring resource use in economic evaluations: determining the social costs of mental illness.
    Clark RE; Teague GB; Ricketts SK; Bush PW; Keller AM; Zubkoff M; Drake RE
    J Ment Health Adm; 1994; 21(1):32-41. PubMed ID: 10131886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.